[CLS] O
Selegiline B
- O
induced O
postural O
hypotension O
in O
Parkinson O
' O
s O
disease O
: O
a O
longitudinal O
study O
on O
the O
effects O
of O
drug O
withdrawal O
. O
[SEP] O

[CLS] O
CONCLUSION O
: O
This O
study O
confirms O
our O
previous O
finding O
that O
selegiline B
in O
combination O
with O
L B
- I
dopa I
is O
associated O
with O
selective O
orthostatic O
hypotension O
. O
[SEP] O

[CLS] O
In O
the O
in O
vivo O
study O
, O
the O
administration O
( O
50 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
of O
TET B
and O
FAN B
in O
mice O
showed O
the O
inhibition O
of O
thrombosis O
by O
55 O
% O
and O
35 O
% O
, O
respectively O
, O
while O
acetylsalicylic B
acid I
( O
ASA B
, O
50 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
a O
positive O
control O
, O
showed O
only O
30 O
% O
inhibition O
. O
[SEP] O

[CLS] O
The O
haemodynamic O
effects O
of O
propofol B
in O
combination O
with O
ephedrine B
in O
elderly O
patients O
( O
ASA O
groups O
3 O
and O
4 O
) O
. O
[SEP] O

[CLS] O
Recent O
reports O
indicate O
that O
single O
agent O
therapy O
with O
vinorelbine B
( O
VNB B
) O
or O
gemcitabine B
( O
GEM B
) O
may O
obtain O
a O
response O
rate O
of O
20 O
- O
30 O
% O
in O
elderly O
patients O
, O
with O
acceptable O
toxicity O
and O
improvement O
in O
symptoms O
and O
quality O
of O
life O
. O
[SEP] O

[CLS] O
A O
selective O
dopamine B
D4 O
receptor O
antagonist O
, O
NRA0160 B
: O
a O
preclinical O
neuropharmacological O
profile O
. O
[SEP] O

[CLS] O
Warfarin B
- O
induced O
artery O
calcification O
is O
accelerated O
by O
growth O
and O
vitamin B
D I
. O
[SEP] O

[CLS] O
High O
doses O
of O
vitamin B
D I
are O
known O
to O
cause O
calcification O
of O
the O
artery O
media O
in O
as O
little O
as O
3 O
to O
4 O
days O
. O
[SEP] O

[CLS] O
From O
such O
experiments O
there O
is O
evidence O
that O
characterization O
and O
detection O
of O
apomorphine B
- O
induced O
activity O
in O
rodents O
critically O
depends O
upon O
the O
test O
conditions O
employed O
. O
[SEP] O

[CLS] O
Tamoxifen B
( O
TAM B
) O
, O
the O
antiestrogenic O
drug O
most O
widely O
prescribed O
in O
the O
chemotherapy O
of O
breast O
cancer O
, O
induces O
changes O
in O
normal O
discoid O
shape O
of O
erythrocytes O
and O
hemolytic O
anemia O
. O
[SEP] O

